Historically localised aggressive non-Hodgkin's lymphoma (NHL) has been treated with involved field radiotherapy (RT) alone, chemotherapy, or a combination of both modalities. The current weight of evidence supports a preference for combined modality treatment (CMT). Increased patient age at diagnosis is well recognised as a poor prognostic indicator in NHL, but despite this some perceive CMT as too toxic for use in the elderly. As a result, some older patients continue to be offered RT alone. Here, we present long-term follow-up of 377 adults of all ages treated with RT alone for early-stage diffuse large-cell lymphoma on British National Lymphoma Investigation trials between 1974 and 1997. 10-year cause-specific survival in patients older than 60 years was poor and significantly inferior to that in younger patients (47 and 75% respectively; P<0.001). There is growing evidence that short-course chemotherapy, with or without RT, is superior to RT alone in early-stage aggressive NHL, in elderly as well as in younger patients. Increased age alone should not exclude patients from systemic treatment for early-stage aggressive NHL.

Keywords: aggressive lymphoma; non-Hodgkin's lymphoma; old age; radiotherapy

Early stage at diagnosis is a significant predictor of improved outcome in aggressive non-Hodgkin’s lymphoma (International Non-Hodgkin’s Lymphoma Prognostic Factors Project, 1993). Until relatively recently treatment with involved field radiotherapy (RT) alone, omitting systemic therapy, was an accepted treatment option in patients with localised disease (Ann Arbor stages I and II). However, the combination of chemotherapy with RT has now become more widely used in early-stage disease (Tondini et al., 1993; Glick et al., 1995; Shenkier et al., 2002), and several investigators have commented that this has coincided with improvement in survival over the past two decades (Mauch et al., 1985; van der Maazen et al., 1998; Tsang and Gospodarowicz, 2001). Two randomised comparisons of combined modality therapy (CMT) against RT alone have confirmed the superiority of CMT (Monfardini et al., 1980; Nissen et al., 1983). Furthermore, CMT using RT and short-course chemotherapy improved survival compared to full-course chemotherapy alone (Miller et al., 1998), although longer follow-up has demonstrated a convergence of both failure-free and overall survival (OS) after 8 years (Miller et al., 2000). Recently, the GELA group have demonstrated superior survival with an intensified chemotherapy regimen alone compared with CMT in low-risk patients (Reyes et al., 2002).

It has been suggested that the toxicity of chemotherapy is disproportionate to any improvement in outcome in elderly patients, and that short-course RT alone is an adequate treatment for this group. There is some evidence that elderly NHL patients experience more morbidity and mortality from chemotherapy (Armitage and Potter, 1984), but performance status (PS) rather than chronological age seems the most significant predictor of treatment-related death (Gomez et al., 1998). Furthermore, the elderly may have more to gain from CMT; increased age is an independent adverse prognostic indicator in aggressive lymphoma (Sutcliffe et al., 1985; Caminsky et al., 1986; International Non-Hodgkin’s Lymphoma Prognostic Factors Project, 1993; Vaughan Hudson et al., 1994; Wylie et al., 1998; Oguchi et al., 2000). There is evidence that the omission of chemotherapy in this age group results in poor outcome. 5-year progression-free survival for a group older than 70 years treated with RT alone was only 31% (Wylie et al., 1998), compared to 70% in patients over 65 years given RT plus short-course chemotherapy (Oguchi et al., 1997).

Data for stage I aggressive lymphoma patients from the British National Lymphoma Investigation (BNLI) have previously shown 10-year disease-free survival (DFS) and OS rates of 45 and 61%, respectively (Vaughan Hudson et al., 1994), comparable to other published series (Jones et al., 1973; Chen et al., 1979; Reddy et al., 1989). Here, we present a retrospective analysis of 377 patients diagnosed with stage IA or IIA diffuse large-cell lymphoma and registered with the BNLI between 1974 and 1997. All patients were treated at presentation with RT alone.

PATIENTS AND METHODS

Patients

We have performed a retrospective analysis of 377 adult patients entered into BNLI studies in the period 1974–1997. In all cases, the
Follow-up of patients treated with radiotherapy for NHL
J Spicer et al

Initial treatment was involved field RT to a dose of 35–40 Gy. The analysis included only patients with a histological diagnosis of diffuse large-cell lymphoma carried out at the treating centre. Central review of histology was performed in all cases. Measurements of serum lactate dehydrogenase (LDH) were not recorded for the early part of this series and so it was not possible to identify accurately patients with raised LDH. Performance status data were not sufficiently complete for analysis. A number of parameters that were recorded, including ESR, were retrospectively analysed along with age and stage as a surrogate for the modified International Prognostic Index (IPI) (Miller et al, 1998). All patients underwent a bone marrow examination that excluded lymphomatous infiltration. Primary gut lymphomas were excluded as these may be a distinct biological entity requiring other treatment modalities (Isaacson and Wright, 1984; Armitage et al, 2001).

Statistical analysis
Complete response (CR) was defined as the disappearance of all signs, symptoms and abnormal investigations due to disease for 3 months after completion of initial therapy. Disease-free survival was measured from the start of treatment to the date of recurrence. Recurrence was defined as the development of tumour following a CR to initial treatment. Overall survival included deaths from all causes, whereas cause-specific survival (CSS) was derived by censoring deaths not due to lymphoma or its treatment. Survival was calculated according to the life-table method, survival curves were calculated according to the Kaplan–Meier method (Kaplan and Meier, 1958) and statistical comparison of curves was performed using the log-rank test (Peto et al, 1971). Multivariate analysis was performed using Cox’s proportional-hazards model (Cox, 1972), the variables included in the analysis being age, stage (Ann-Arbor I or II), PS, sex, disease site, ESR, haemoglobin concentration and the variables included in the analysis being age, stage as a surrogate for the modified International Prognostic Index (IPI) (Miller et al, 1998). All patients underwent a bone marrow examination that excluded lymphomatous infiltration. Primary gut lymphomas were excluded as these may be a distinct biological entity requiring other treatment modalities (Isaacson and Wright, 1984; Armitage et al, 2001).

RESULTS

Patient characteristics
In all, 424 patients were treated with RT alone for early-stage diffuse large-cell lymphoma and were registered with the BNLI during the accrual period. 47 individuals were excluded at registration because of previous malignancy, incomplete staging or lack of other baseline data, thus this analysis was confined to the remaining 377 patients. Median follow-up to date for this group is 12.7 years. There were 202 males and 175 females. Median age was 59 years (range 17–89 years). Patient characteristics are outlined in Table 1.

Table 1 Patient characteristics

| No. of patients | Median age (range) (years) | Sex ratio (male:female) | Stage IA | Stage IIA |
|-----------------|---------------------------|------------------------|----------|----------|
|                 |                           |                        | 292 (77%)| 85 (23%) |

Disease site
- Nodal disease only 189 (50%)
- Extranodal 136 (36%)
- Nodal and extranodal 49 (13%)
- Unknown 3 (1%)

Disease site
Nodal and extranodal 136 (36%)
Nodal disease only 189 (50%)
Extranodal 136 (36%)
Nodal and extranodal 49 (13%)
Unknown 3 (1%)

Results of treatment
A total of 294 patients (78%) achieved a complete remission. The complete remission rate for patients aged less than 60 years was 80%, and for older patients 77%. The CR rates for stages I and II disease were 85 and 58%, respectively. Of those patients achieving complete remission, 57% remained disease free at 10 years. The percentage of all treated patients remaining disease free at 10 years was 44%. The great majority of relapses occurred within the first 5 years following initial treatment. The OS at 10 years was 51%, rising to 63% when patients dying from causes other than lymphoma or its treatment were excluded.

Subgroup analysis
Univariate analysis of DFS identified age (≥60 years), stage (II vs I), ESR (≥40 mm h⁻¹) and serum albumin (<40 g l⁻¹), but not haemoglobin, as factors related to inferior DFS. Lactate dehydrogenase was not recorded for many of the patients in this series. Multivariate Cox’s regression analysis of DFS identified age (relative risk (RR) 1.45, 95% confidence interval 1.07 – 2.00), stage (RR 2.19, 95% CI 1.57 – 3.04) and ESR (RR 2.15, 95% CI 1.30 – 3.55) as significant risk factors related to relapse. The DFS at 10 years for the patients aged 60 years and over was 35%, compared to 52% for the younger group. The percentage of patients in each stage and age group remaining disease free following initial RT is shown in Figures 1 and 2.

Figure 1 Percentage of patients with early aggressive NHL remaining disease free after initial RT according to stage.

Figure 2 Percentage of patients with early aggressive NHL remaining disease free after initial RT according to age.
with 75% for younger patients. 10-year DFS was similarly poor in the elderly (35% for patients older than 60 years and 52% for those younger). The similarity between DFS and CSS in this group is indicative of the failure of salvage therapy to produce meaningful survival benefit, although details of salvage treatment are not available.

This analysis includes 38 patients treated before 1980 and 255 treated before 1990. Disease-free survival, but not OS or CSS, was significantly superior in patients treated more recently (not shown). However, differences between DFS, OS and CSS for the two age groups remained highly significant when only those patients treated since 1990 were analysed ($P = 0.004$, $< 0.001$ and $< 0.001$, respectively). This suggests that the inferior results for older patients reported here do not merely reflect obsolete standards of diagnosis, treatment or supportive care.

In addition to age and stage, multivariate analysis found ESR to be an adverse predictor of DFS. Like LDH, which was not recorded in the earlier years of this series, ESR is likely to serve as a surrogate for disease activity. Similarly, albumin is an independent predictor of CSS. Like ESR, albumin may correlate with disease activity, but may also integrate a measure of comorbidity, which was not itself recorded but is likely to be a predictor of poor outcome in older patients.

The poor outcome in elderly patients treated with RT alone suggests that this group should also be offered systemic therapy. The perception that the elderly respond to and tolerate chemotherapy poorly is not necessarily supported by the evidence (Jones et al., 1989), and short-course chemotherapy was originally specifically designed for the elderly (O’Reilly et al., 1990). Algorithms have been developed that allow the identification of elderly patients who are more or less functionally impaired by the ageing process (Saliba et al., 2001). This method may be used to select patients for treatment according to their true fitness rather than by chronological age alone. Nevertheless, ageing is associated with reduced functional reserve in many organ systems including bone marrow (Chatta and Dale, 1996). This has been perceived as a major barrier to systemic chemotherapy in the elderly because myelosuppression is the most frequent dose-limiting toxicity of such treatment. However, recombinant growth factors are now widely available and are effective in many tumour types including aggressive NHL (Pettengell et al., 1992; Zinzani et al., 1997). The benefits of growth factors extend to the elderly despite their depleted reserve (Balducci and Lyman, 2001).

A recent comparison of short-course CHOP chemotherapy with or without involved field RT in elderly patients with localised disease showed equivalent overall and CSS in the two groups (Fillet et al., 2002). This implies that the addition of RT to short-course chemotherapy provides no additional benefit. Indeed, the addition of RT may be detrimental in the oldest patients as subgroup analysis showed superior OS following chemotherapy alone in those over 69 years (Fillet et al., 2002).

**DISCUSSION**

The overall CR rate of 78%, and 10 year DFS, OS and CSS rates of 44, 51 and 63%, respectively, are comparable with those achieved by other groups treating early NHL with RT alone (Timothy et al., 1980; Hagberg et al., 1989). Failure to achieve CR was generally due to the appearance of disease elsewhere, not detected at staging, within 3 months of treatment, rather than a result of radiation resistance. Multivariate analysis reveals groups of patients with significantly poorer prognosis. Increased age and stage are recognised as adverse components of the IPI in NHL (International Non-Hodgkin’s Lymphoma Prognostic Factors Project, 1993), and old age was included in the modified IPI applied to early-stage NHL (Miller et al., 1998). Elderly and younger patients in this BNLI series enjoyed similar response rates following treatment with RT alone; however, in the elderly survival was significantly inferior. CSS at 10 years was 47% in patients older than 60 years compared to those with more advanced (stage II) disease in the younger group.
The poor outcome reported here for older patients treated with RT alone, even when selected for early stage, indicates that chemotherapy should not be omitted in the elderly for the reason that their age in itself predicts poor outcome. Thus fit older patients with early-stage lymphoma should be offered CMT or even chemotherapy alone.

REFERENCES

Armitage JO, Mauch P, Harris NL, Bierman P (2001) Non-Hodgkin’s lymphomas. In Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S and Rosenberg SA (eds) pp 2256 – 2316. Philadelphia: Lippincott Williams and Wilkins

Armitage JO, Potter JF (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 32: 269 – 273

Balducci L, Lyman GH (2001) Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol 19: 1583 – 1585

Chatta GS, Dale DC (1996) Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors. Drugs Aging 9: 37 – 47

Chen MG, Prosnitz LR, Gonzalez-Serva A, Fischer DB (1979) Results of the International Non-Hodgkin’s Lymphoma Prognostic Factors Project. J Clin Oncol 7: 1245 – 1254

Cox D (1972) Regression models and life tables. J R Stat Soc Ser B 34: 187 – 220

Fellet G, Bonnet C, Mounier N, Thieblemont C, Ferme C, Quesnez B, Martin C, Blanc M, Conroy T, Penny A, Petrella T, Reyes F (2002) Radiotherapy is unnecessary in elderly patients with localized aggressive non-Hodgkin’s lymphoma: results of the GELA LNH93-4 study. Blood 111: 3374 – 3378

Glick JH, Kim K, Earle J, O’Connell MJ (1995) An ECOG randomised Phase III trial of CHOP vs CHOP+radiotherapy for intermediate grade early stage non-Hodgkin’s lymphoma. In Proceedings of the Annual Meeting of the American Society of Clinical Oncology, p 391, Alexandria, VA: ASCO

Gomez H, Hidalgo M, Casanova L, Colomer R, Pen DL, Otero J, Rodriguez H, Barraco C, Cortes-Funes H, Vallejos C (1998) Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin’s lymphoma: results of a multivariate analysis. J Clin Oncol 16: 2065 – 2069

Hagberg H, Pettersson U, Glimmelius B, Sundstrom C (1989) Prognostic factors in non-Hodgkin lymphoma stage I treated with radiotherapy. Acta Oncol 28: 45 – 50

International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329: 987 – 994

Isaacson P, Wright D (1984) Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 53: 2515 – 2524

Jones S, Miller T, Connors J (1989) Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 7: 1186 – 1191

Jones SE, Futks Z, Kaplan HS, Rosenberg SA (1973) Non-Hodgkin’s lymphomas. V, Results of radiotherapy. Cancer 32: 682 – 691

Kaminiski MS, Coleman CN, Colby TV, Cox RS, Rosenberg SA (1986) Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 104: 747 – 756

Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457 – 481

Mauch P, Leonard R, Skarin A, Rosenthal D, Come S, Chaffey J, Hellman S, Canellos G (1985) Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I – II non-Hodgkin’s lymphomas. J Clin Oncol 3: 1301 – 1308

Miller PF, Dahlberg S, Cassidy JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI (1996) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade aggressive non-Hodgkin’s lymphoma. N Engl J Med 339: 21 – 26

Miller TP, Leblanc M, Chase E, Fisher RI (2000) Chemotherapy alone compared with chemotherapy plus radiotherapy for early stage aggressive non-Hodgkin’s lymphoma: update of the Southwest Oncology Group randomized trial. In First International Symposium on Biology and Treatment of Aggressive Lymphomas. Germany: Saarbrucken

Monfardini S, Banfi A, Bonadonna G, Rilke F, Milani F, Valagussa P, Lattuada A (1980) Improved five year survival after combined radiotherapy – chemotherapy for stage I – II non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 6: 125 – 134

Nissen NI, Erboll J, Hansen HS, Walbom-Jorgensen S, Pedersen-Bjergaard J, Hansen MM, Rygard J (1983) A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I – II non-Hodgkin’s lymphomas. Cancer 52: 1 – 7

Oguchi M, Ikeda H, Isole K, Hirota S, Hasegawa M, Nakamura K, Sasaki K, Hayabuchi N (2000) Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin’s lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys 48: 161 – 168

Oguchi M, Izuon I, Takei K, Shikama N, Sasaki G, Gomi K, Sone S (1997) Treatment for non-Hodgkin’s lymphoma (stage I, II) of the elderly: usefulness of local and regional irradiation and reduced dose chemotherapy. Int J Radiat Oncol Biol Phys 37: 87 – 92

O’Reilly SE, Haskins P, Klasa R, Klimo P, Connors J (1996) Chemotherapy for elderly patients with advanced stage large cell lymphoma – a little goes a long way. In Fourth International Conference on Malignant Lymphoma, Ullmann, JE (ed.). Kluwer Academic Publishers

Peto R, Pike M, Armitage C, Breslow N, Cox D, Howard S, Mantel N, McPherson K, Peto J, Smith P (1971) Design and analysis of randomised clinical trials requiring prolonged observations of each patient II. Analysis and examples. Br J Cancer 35: 1 – 39

Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 80: 1430 – 1436

Reddy S, Saxena VS, Pellettiere EV, Hendrickson FR (1989) Stage I and II non-Hodgkin’s lymphomas: long-term results of radiation therapy. Int J Radiat Oncol Biol Phys 16: 687 – 692

Reyes F, Lepage E, Munck J, Morel P, Coiffier B, Lederlin P, Simon D, Bosly A, Fabiani B, Bordesoule D, Ganem G, Tilly H (2002) Superiority of chemotherapy alone with the ACVBP regimen over treatment with three cycles of CHOP plus radiotherapy in low risk localized aggressive lymphoma: the LNH93-1 GELA study. Blood 111: 343a

Saliba D, Elliott M, Rubenstein LZ, Solomon DH, Young RT, Kamberg CJ, Roth C, MacLean CH, Shekelle PG, Sloss EM, Wenger NS (2001) The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49: 1691 – 1699

Shenkier TN, Voss N, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Klimo P, O’Reilly SE, Sutcliffe S, Connors JM (2002) Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20: 197 – 204

Sutcliffe SB, Gospodarowicz MK, Bush RS, Brown TC, Chua T, Bean HA, Clark RM, Dembo A, Fitzpatrick PJ, Peters MV (1985) Role of radiation therapy in localized non-Hodgkin’s lymphoma. Radiother Oncol 4: 211 – 223

Timothy A, Lister T, Katz D, Jones A (1980) Localized non-Hodgkin’s lymphoma. Eur J Cancer 16: 799 – 807

Tondini C, Zanini M, Lombardi F, Bengala C, Rocca A, Giardini R, Buzzoni R, Valagussa P, Bonadonna G (1993) Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin’s lymphomas. J Clin Oncol 11: 720 – 725

Tsang RW, Gospodarowicz MK (2001) Management of localized (stage I and II) clinically aggressive lymphomas. Ann Hematol 80(Suppl 3): B66 – B72

ACKNOWLEDGEMENTS

We thank Cancer Research UK and the Lymphoma Research Trust for their financial support and all the clinicians who registered patients with the BNLI.
van der Maazen RW, Noordijk EM, Thomas J, Raemaekers JM, Meerwaldt JH (1998) Combined modality treatment is the treatment of choice for stage I/IE intermediate and high grade non-Hodgkin's lymphomas. *Radiother Oncol* **49**: 1–7

Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, Anderson L, Linch DC (1994) Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. *Br J Cancer* **69**: 1088–1093

Wylie JP, Cowan RA, Deakin DP (1998) The role of radiotherapy in the treatment of localised intermediate and high grade non-Hodgkin's lymphoma in elderly patients. *Radiother Oncol* **49**: 9–14

Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendaishi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S (1997) Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. *Blood* **89**: 3974–3979